Accès gratuit
| Numéro |
Med Sci (Paris)
Volume 35, Numéro 12, Décembre 2019
Anticorps monoclonaux en thérapeutique
|
|
|---|---|---|
| Page(s) | 1160 - 1162 | |
| Section | Bioproduction | |
| DOI | https://doi.org/10.1051/medsci/2019220 | |
| Publié en ligne | 6 janvier 2020 | |
- Sibéril S, de Romeuf C, Bihoreau N, et al. Selection of a human anti-RhD monoclonal antibody for therapeutic use: impact of IgG glycosylation on activating and inhibitory Fc gamma R functions. Clin Immunol 2006 ; 118: 170–179. [CrossRef] [PubMed] [Google Scholar]
- Béliard R, Waegemans T, Notelet D, et al. A human anti-D monoclonal antibody selected for enhanced FcgammaRIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies. Br J Haematol 2008 ; 141: 109–119. [CrossRef] [PubMed] [Google Scholar]
- Yver A, Homery MC, Fuseau E, et al. Pharmacokinetics and safety of roledumab, a novel human recombinant monoclonal anti-RhD antibody with an optimized Fc for improved engagement of FcγRIII, in healthy volunteers. Vox Sang 2012 ; 103: 213–222. [CrossRef] [PubMed] [Google Scholar]
- de Romeuf C, Dutertre CA, Le Garff-Tavernier M, et al. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16. Br J Haematol 2008 ; 140: 635–643. [CrossRef] [PubMed] [Google Scholar]
- Le Garff-Tavernier M, Decocq J, de Romeuf C, et al. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies. Leukemia 2011 ; 25: 101–109. [CrossRef] [PubMed] [Google Scholar]
- Le Garff-Tavernier M, Herbi L, de Romeuf C, et al. Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion. Leukemia 2014 ; 28: 230–233. [CrossRef] [PubMed] [Google Scholar]
- Sharman JP, Farber CM, Mahadevan D, et al. Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial. Br J Haematol 2017 ; 176: 412–420. [CrossRef] [PubMed] [Google Scholar]
- Sawas A, Farber CM, Schreeder MT, et al. A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab. Br J Haematol 2017 ; 177: 243–253. [CrossRef] [PubMed] [Google Scholar]
- Nastoupil LJ, Lunning MA, Vose JM, et al. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. Lancet Haematol 2019 ; 6: e100–e109. [CrossRef] [PubMed] [Google Scholar]
- Lovett-Racke AE, Gormley M, Liu Y, et al. B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients. J Neuroimmunol 2019 ; 332: 187–197. [CrossRef] [PubMed] [Google Scholar]
- Estupina P, Fontayne A, Barret JM, et al. The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells. Oncotarget 2017 ; 8: 37061–37079. [CrossRef] [PubMed] [Google Scholar]
- Bougherara H, Némati F, Nicolas A, et al. The humanized anti-human AMHRII mAb 3C23K exerts an anti-tumor activity against human ovarian cancer through tumor-associated macrophages. Oncotarget 2017 ; 8: 99950–99965. [CrossRef] [PubMed] [Google Scholar]
- Fournier N, Jacque E, Fontayne A, Improved in vitro and in vivo activity against CD303-expressing targets of the chimeric 122A2 antibody selected for specific glycosylation pattern. 2018; 10: 651–63. [Google Scholar]
- Urbain R, Teillaud JL, Prost JF. Les anticorps EMABling®. De la prophylaxie de l’allo-immunisation fœto-maternelle au traitement de la leucémie lymphoïde chronique. Med Sci (Paris) 2009 ; 25: 1141–1144. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.
Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.
Le chargement des statistiques peut être long.